BioVie Inc. (BIVI) Stock Analysis & Investment Frameworks
BioVie Inc. (BIVI) stock analysis on Invetso. Review BioVie Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
BioVie Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
BioVie Inc. Key Financial Metrics
- Market Cap: $11.63M
- Revenue: $N/A
- ROE: -126.02%
- ROIC: -214.80%
- Dividend Yield: N/A
About BioVie Inc.
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease. Further preclinical investigations are underway for NE3107, exploring its potential applications in treating multiple myeloma and prostate cancer. Established in 2013, the company adopted its current name, BioVie Inc., in July 2016, having previously operated as NanoAntibiotics, Inc. Its corporate headquarters are situated in Carson City, Nevada.
BioVie Inc. Investment Frameworks
Invetso analyzes BioVie Inc. (BIVI) across the following frameworks:
- BioVie Inc. 10Y Growth Potential
- BioVie Inc. Scenario Analysis
- BioVie Inc. Risks & Opportunities
- BioVie Inc. Economic Moat
- BioVie Inc. Business Model
- BioVie Inc. Management
- BioVie Inc. SWOT Analysis
- BioVie Inc. Porter's 5 Forces
- BioVie Inc. PESTLE Analysis
- BioVie Inc. ESG Analysis